Trials / Recruiting
RecruitingNCT06895928
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
A Phase II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A2102 | SHR-A2102 for injection. |
| DRUG | Bevacizumab Injection | Bevacizumab injection. |
| DRUG | Adebelimab Injection | Adebelimab injection. |
| DRUG | Ametinib Mesylate Tablets | Ametinib mesylate tablets. |
| DRUG | Osimertinib Mesylate Tablets | Osimertinib mesylate tablets. |
Timeline
- Start date
- 2025-03-28
- Primary completion
- 2028-12-01
- Completion
- 2028-12-01
- First posted
- 2025-03-26
- Last updated
- 2025-04-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06895928. Inclusion in this directory is not an endorsement.